Skip to main content

Camp4 Therapeutics Corp

CAMP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001736730

In the last 90 days, Camp4 Therapeutics Corp insiders filed 5 open-market purchases and 4 sales; 61 institutions reported holding it in 13F filings for Q2 2026, worth $182.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Camp4 Therapeutics Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
5 filings
4 insiders, $99.1K in total
Open-market sells
4 filings
2 insiders, $2.50M in total
Insiders trading
6
Net value
−$2.40M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Camp4 Therapeutics Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Camp4 Therapeutics Corp
NameTitleLast reported holdingLast filingFilings, past year
Gold KellyChief Financial Officer10,000IndirectSep 2, 20264
Schwab Andrew J.Director2,033,270IndirectAug 31, 20265
Tardiff DanielChief Scientific Officer0Aug 19, 20263
Parmar Kush10% Owner2,941,176IndirectAug 5, 20261
5AM Ventures VI, L.P.10% Owner2,941,176IndirectAug 5, 20261
5AM Partners VI, LLC10% Owner2,941,176IndirectAug 5, 20261
5AM Opportunities II, L.P.10% Owner2,941,176IndirectAug 5, 20261
5AM Ventures VII, L.P.10% Owner2,941,176IndirectAug 5, 20261
5AM Opportunities II (GP), LLC10% Owner2,941,176IndirectAug 5, 20261
5AM Partners VII, LLC10% Owner2,941,176IndirectAug 5, 20261
Young Richard ADirector186,388Aug 5, 20262
Maricich YuriChief Medical Officer12,611Aug 5, 20263
Mandel-Brehm JoshChief Executive Officer284,968Aug 5, 20263
Williams Douglas EDirector–Jun 12, 20261
Holtzman Steven HDirector108,946Jun 12, 20261
Nashat AmirDirector, 10% Owner197,661IndirectJun 12, 20261
Stewart MurrayDirector–Jun 12, 20261
MacLean Michael FDirector–Apr 3, 20261
Chee Brian10% Owner197,661IndirectSep 11, 20250
Schulman Amy W10% Owner197,661IndirectSep 11, 20250
Polaris Partners VII, L.P.10% Owner197,661IndirectSep 11, 20250
Polaris Entrepreneurs' Fund VII, L.P.10% Owner197,661IndirectSep 11, 20250
Polaris Management Co. VII, L.L.C.10% Owner197,661IndirectSep 11, 20250
Polaris Partners GP X, L.L.C.10% Owner197,661IndirectSep 11, 20250
Polaris Partners X, L.P.10% Owner197,661IndirectSep 11, 20250
Higgins Michael JDirector–Jun 27, 20250
Ragan PaulaDirector–Jun 27, 20250
Boylan James PDirector–Jun 27, 20250
Thadhani Ravi I.Director–Jun 27, 20250
Bumcrot DavidChief Scientific Officer–Apr 3, 20250
Northpond Ventures GP, LLC10% Owner763,636IndirectOct 17, 20240
Northpond Ventures, LP10% Owner763,636IndirectOct 17, 20240
Rubin Michael P.10% Owner763,636IndirectOct 17, 20240
Northpond Ventures II GP, LLC10% Owner763,636IndirectOct 17, 20240
Northpond Ventures II, LP10% Owner763,636IndirectOct 17, 20240
Northpond Ventures III, LP10% Owner763,636IndirectOct 17, 20240
Northpond Ventures III GP, LLC10% Owner763,636IndirectOct 17, 20240
Andreessen Marc L10% Owner545,454IndirectOct 17, 20240
Horowitz Benjamin A10% Owner545,454IndirectOct 17, 20240
AH Equity Partners Bio I, L.L.C.10% Owner545,454IndirectOct 17, 20240
AH Bio Fund I, L.P.10% Owner545,454IndirectOct 17, 20240
AH Bio Fund IV, L.P.10% Owner545,454IndirectOct 17, 20240
AH Equity Partners Bio IV, L.L.C.10% Owner545,454IndirectOct 17, 20240
Enavate Sciences GP, LLC10% Owner3,785,802IndirectOct 17, 20240
Everest Aggregator, LP10% Owner3,785,802IndirectOct 17, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 2, 2026 (view filing)7:50 PM ETAug 312 daysGold KellyChief Financial OfficerPPurchase+10.0K$3.96+$39.6KNew position10.0K after
Aug 31, 2026 (view filing)5:05 PM ETAug 274 daysSchwab Andrew J.DirectorSSale−400.0K$4.04−$1.62M−16.4%2.03M after
Aug 26, 2026 (view filing)4:57 PM ETAug 242 daysSchwab Andrew J.DirectorSSale−10$4.50−$450.0%2.43M after
Aug 21, 2026 (view filing)4:59 PM ETAug 19-212 daysSchwab Andrew J.DirectorSSale−191.9K$4.59−$879.7K−7.3%2.43M after3 lots
Aug 19, 2026 (view filing)8:46 PM ETAug 19Same dayTardiff DanielChief Scientific OfficerSSale−1.74K$4.76−$8.27K−100.0%0 after
Aug 5, 2026 (view filing)5:39 PM ETAug 32 daysParmar Kush and 6 others10% OwnerPPurchase+3.18M$1.53+$4.86M–3.18M afterDerivative
Aug 5, 2026 (view filing)5:09 PM ETAug 32 daysYoung Richard ADirectorPPurchase+16.4K$1.65+$27.0K+9.6%186.4K after
Aug 5, 2026 (view filing)5:08 PM ETAug 32 daysMaricich YuriChief Medical OfficerPPurchase+6.55K$1.65+$10.8K+108.1%12.6K after
Aug 5, 2026 (view filing)5:08 PM ETAug 32 daysGold KellyChief Financial OfficerPPurchase+6.55K$1.65+$10.8K+9.7%74.4K after
Aug 5, 2026 (view filing)5:07 PM ETAug 32 daysMandel-Brehm JoshChief Executive OfficerPPurchase+6.55K$1.65+$10.8K+2.4%285.0K after
Sep 15, 2025 (view filing)8:12 PM ETSep 114 daysParmar Kush and 6 others10% OwnerPPurchase+2.94M$1.53+$4.50MNew position2.94M after
Sep 11, 2025 (view filing)4:59 PM ETSep 11Same dayChee Brian and 6 others10% OwnerPPurchase+1.31M$1.53+$2.00MNew position197.7K after2 lotsDuplicate filing
Sep 11, 2025 (view filing)Sep 11Same dayGold KellyChief Financial OfficerPPurchase+6.06K$1.65+$10.0K+9.8%67.9K after
Sep 11, 2025 (view filing)Sep 11Same dayMandel-Brehm JoshChief Executive OfficerPPurchase+6.06K$1.65+$10.0K+2.2%278.4K after
Sep 11, 2025 (view filing)Sep 11Same dayMaricich YuriChief Medical OfficerPPurchase+6.06K$1.65+$10.0KNew position6.06K after
Sep 11, 2025 (view filing)Sep 11Same dayYoung Richard ADirectorPPurchase+15.2K$1.65+$25.0K+9.8%170.0K after
Sep 11, 2025 (view filing)Sep 11Same dayNashat AmirDirector, 10% OwnerPPurchase+1.31M$1.53+$2.00MNew position197.7K after2 lots
Oct 22, 2024 (view filing)5:31 PM ETOct 157 daysChee Brian and 6 others10% OwnerPPurchase+909.1K$11.00+$10.0MNew position909.1K afterAmendedDuplicate filing
Oct 17, 2024 (view filing)6:34 PM ETOct 152 daysNorthpond Ventures GP, LLC and 6 others10% OwnerPPurchase+763.6K$11.00+$8.40MNew position763.6K after
Oct 17, 2024 (view filing)5:05 PM ETOct 152 daysAndreessen Marc L and 5 others10% OwnerPPurchase+727.3K$11.00+$8.00MNew position545.5K after2 lots
Oct 17, 2024 (view filing)4:15 PM ETOct 152 daysEnavate Sciences GP, LLC and 1 other10% OwnerPPurchase+1.36M$11.00+$15.0M+56.3%3.79M after
Oct 15, 2024 (view filing)6:00 PM ETOct 15Same daySchulman Amy W and 5 others10% OwnerPPurchase+909.1K$11.00+$10.0MNew position909.1K afterDuplicate filing
Oct 15, 2024 (view filing)5:56 PM ETOct 15Same dayParmar Kush and 4 others10% OwnerPPurchase+909.1K$11.00+$10.0M+53.0%2.63M afterDuplicate filing
Oct 15, 2024 (view filing)Oct 15Same dayNashat AmirDirector, 10% OwnerPPurchase+909.1K$11.00+$10.0MNew position909.1K after
Oct 15, 2024 (view filing)Oct 15Same daySchwab Andrew J.Director, 10% OwnerPPurchase+909.1K$11.00+$10.0M+53.0%2.63M after